DE60139305D1 - Zusammensetzung aus antigen und glykolipid zur sublingualen verabreichung - Google Patents

Zusammensetzung aus antigen und glykolipid zur sublingualen verabreichung

Info

Publication number
DE60139305D1
DE60139305D1 DE60139305T DE60139305T DE60139305D1 DE 60139305 D1 DE60139305 D1 DE 60139305D1 DE 60139305 T DE60139305 T DE 60139305T DE 60139305 T DE60139305 T DE 60139305T DE 60139305 D1 DE60139305 D1 DE 60139305D1
Authority
DE
Germany
Prior art keywords
glycolipide
antigen
sub
composition
lingual administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139305T
Other languages
English (en)
Inventor
Alan Wheeler
Garry Elliott
Christopher Wallace Cluff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergy Therapeutics UK Ltd
Corixa Corp
Original Assignee
Allergy Therapeutics UK Ltd
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9883730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60139305(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergy Therapeutics UK Ltd, Corixa Corp filed Critical Allergy Therapeutics UK Ltd
Application granted granted Critical
Publication of DE60139305D1 publication Critical patent/DE60139305D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE60139305T 2000-01-14 2001-01-15 Zusammensetzung aus antigen und glykolipid zur sublingualen verabreichung Expired - Lifetime DE60139305D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0000891.2A GB0000891D0 (en) 2000-01-14 2000-01-14 Formulation
PCT/GB2001/000142 WO2001051082A1 (en) 2000-01-14 2001-01-15 Composition of antigen and glycolipid adjuvant sublingual administration

Publications (1)

Publication Number Publication Date
DE60139305D1 true DE60139305D1 (de) 2009-09-03

Family

ID=9883730

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139305T Expired - Lifetime DE60139305D1 (de) 2000-01-14 2001-01-15 Zusammensetzung aus antigen und glykolipid zur sublingualen verabreichung

Country Status (15)

Country Link
US (1) US8470331B2 (de)
EP (3) EP2322212A1 (de)
JP (1) JP4648603B2 (de)
AR (1) AR027924A1 (de)
AU (1) AU2001228625A1 (de)
CA (1) CA2397359C (de)
CZ (1) CZ304941B6 (de)
DE (1) DE60139305D1 (de)
DK (1) DK2100616T3 (de)
ES (2) ES2328336T5 (de)
GB (2) GB0000891D0 (de)
HU (1) HU230545B1 (de)
PL (1) PL356963A1 (de)
SK (1) SK288411B6 (de)
WO (1) WO2001051082A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2005115449A1 (en) * 2004-05-28 2005-12-08 Alk-Abelló A/S Method of treating allergy and infection by eliciting an iga antibody response
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
TR201807756T4 (tr) 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9545455B2 (en) * 2009-04-29 2017-01-17 Pravin K. Muniyappa Device and method for the diagnosis of gastrointestinal allergy
EP2437753B1 (de) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen die diese enthalten
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP5650780B2 (ja) 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
JP2023518924A (ja) * 2020-03-24 2023-05-09 チョル アン，ビョン 幼い哺乳動物の粘膜関連伝染性疾病を予防または治療するための血清組成物の製造方法、前記方法によって製造された血清組成物及びその用途
KR102151962B1 (ko) 2020-03-24 2020-09-04 안병철 어린 포유동물의 전염성 질병을 예방 또는 치료하기 위한 혈청 조성물의 제조방법, 상기 방법에 의해 제조된 혈청 조성물 및 이의 용도

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128637A (en) 1966-09-13 1968-09-25 Beecham Group Ltd Influenza vaccine
US3541201A (en) 1968-12-18 1970-11-17 Ethan Alan Brown Novel sodium chloride encapsulated injectionable substances
GB1377074A (en) * 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
GB1492973A (en) 1974-02-16 1977-11-23 Beecham Group Ltd Process for preparing injectable compositions
US4070455A (en) * 1974-02-16 1978-01-24 Beecham Group Limited Process for preparing injectable desensitizing compositions and products thereof in microparticle form
EP0182442B2 (de) 1978-12-22 1996-04-03 Biogen, Inc. Rekombinante DNS-Moleküle und Verfahren zur Herstellung derselben
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3521994A1 (de) * 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
US4975420A (en) * 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
FR2621916B1 (fr) * 1987-10-19 1990-03-09 Bioeurope Derives de la l-tyrosine solubles dans l'eau et procede pour leur preparation
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
CA2131442A1 (en) * 1992-03-03 1993-09-04 Seishi Tsuchiya Oral vaccine
ES2143716T3 (es) * 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
BR9405996A (pt) * 1993-03-11 1995-12-19 Secretech Inc Mucoadesivos poliméricos na distribuição de imunógenos em superfícies mucosais
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
ATE196737T1 (de) * 1993-05-25 2000-10-15 American Cyanamid Co Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
JPH09502604A (ja) 1993-08-27 1997-03-18 エンテリック リサーチ ラボラトリーズ インコーポレイテッド Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ抗原、並びにそれらの製造及び利用
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5646115A (en) * 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
WO1996025664A1 (en) 1995-02-17 1996-08-22 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
GB9508785D0 (en) 1995-04-29 1995-06-21 Smithkline Beecham Plc Novel compositions
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
JP2001519781A (ja) 1997-03-10 2001-10-23 バイエル・コーポレーシヨン ワクチンとしてのウシの呼吸器および腸コロナウイルス
TR199902437T2 (xx) * 1997-04-01 2000-01-21 Corixa Corporation Monofosforil lipid A'ya ait sulu im�nolojik adjuvant terkipleri.
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
AU7983198A (en) * 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
EP1029053A1 (de) * 1997-11-10 2000-08-23 Statens Seruminstitut Nukleinsäurefragmente und polypeptide von mycobacterium tuberculosis
WO1999064074A1 (en) 1998-06-11 1999-12-16 The Trustees Of The University Of Pennsylvania Methods and compositions for delivering proteins to macrophage cells and cells of macrophage derived lineage
CA2330209A1 (en) 1998-06-12 1999-12-23 Smithkline Beecham Biologicals S.A. Recombinant production of toxoplasma sag1 antigen
CA2337823A1 (en) * 1998-06-26 2000-01-06 Bernard Meignier Mucosal targeting immunisation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
EP1031347B1 (de) 1999-01-27 2002-04-17 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
AU4673099A (en) * 1999-02-26 2000-09-14 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
TR200103046T2 (tr) * 1999-04-23 2002-06-21 Pharmexa A/S IL5 aktivitesini düşürmek için yöntem.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000076476A1 (en) 1999-06-11 2000-12-21 Endorex Corporation Adjuvant-containing polymerized liposomes for oral, mucosal or intranasal vaccination
GB9924529D0 (en) * 1999-10-15 1999-12-15 Smithkline Beecham Biolog Novel compounds
WO2001095914A1 (en) * 2000-06-14 2001-12-20 William Leslie Porter Lipids for modulating immune response
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition

Also Published As

Publication number Publication date
GB2360210A (en) 2001-09-19
ES2328336T5 (es) 2016-06-21
US20030165512A1 (en) 2003-09-04
AR027924A1 (es) 2003-04-16
GB0101035D0 (en) 2001-02-28
SK10412002A3 (sk) 2003-05-02
HUP0203972A3 (en) 2011-02-28
EP1255563A1 (de) 2002-11-13
JP4648603B2 (ja) 2011-03-09
EP2100616B1 (de) 2015-11-25
CA2397359C (en) 2012-06-05
CA2397359A1 (en) 2001-07-19
CZ20022417A3 (cs) 2003-03-12
ES2561360T3 (es) 2016-02-25
GB0000891D0 (en) 2000-03-08
DK2100616T3 (en) 2016-02-08
EP1255563B2 (de) 2016-03-02
EP2100616A3 (de) 2009-09-23
SK288411B6 (sk) 2016-10-03
EP2100616A2 (de) 2009-09-16
JP2003519669A (ja) 2003-06-24
EP1255563B1 (de) 2009-07-22
CZ304941B6 (cs) 2015-02-04
US8470331B2 (en) 2013-06-25
HUP0203972A2 (hu) 2003-03-28
EP2322212A1 (de) 2011-05-18
HU230545B1 (hu) 2016-11-28
GB2360210B (en) 2004-12-15
PL356963A1 (en) 2004-07-12
WO2001051082A1 (en) 2001-07-19
ES2328336T3 (es) 2009-11-12
AU2001228625A1 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
DE60139305D1 (de) Zusammensetzung aus antigen und glykolipid zur sublingualen verabreichung
DE60121992D1 (de) Zusammensetzung zur verabreichung und beschichtung medizinischer geräte
ATE510555T1 (de) Chemisch modifizierte neue erythropoietin- stimulierende protein zusammensetzungen und verfahren
ATE368018T1 (de) Gipszusammensetzungen und dazugehörende verfahren
DE60132108D1 (de) Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion
DE50112013D1 (de) Deodorantien und antiperspirantien
DE60041782D1 (de) Bioaktiver und osteoporotischer knochenzement
DE60140895D1 (de) Zusammensetzung und verfahren
DE60224691D1 (de) Keramisches hybridmaterial aus keramischen isolier- und konstruktionsschichten
ATE381947T1 (de) Zusammensetzungen enthaltend piperacillin und tazobactam zur injektion
DE60144334D1 (de) Myostatin-antagonisten und Verwendungen davon
DE60130791D1 (de) Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
NO20011798L (no) Fremgangsmåte for å forbedre strömningsegenskapene til sement- og ikke-sementmaterialer
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
DE60140736D1 (de) Wabenförmige struktur und verfahren zur herstellung derselben
ATE319406T1 (de) Kompositmaterialien aus calciumverbindungen und proteinkomponenten
DE60231077D1 (de) Resistzusammensetzung und Verfahren zur Herstellung von Halbleiterbauelementen
DE10294402D2 (de) Estrogen-Gestagen Kombinationspräparat und Anwendung
DE60035254D1 (de) Verpackung für Dentalmaterialien und Verwendungsverfahren
DE60139422D1 (de) Polyarylenether-polyolefinzusammensetzung und formassen daraus
FI20020760A (fi) Verkkotunnuksen rekisteröinti ja käyttö
DE60144265D1 (de) Halbleiterbauelement und dessen herstelllung
DE60118276D1 (de) Wärmeleitendes Material und Verfahren zu seiner Herstellung
DE60115467D1 (de) Herstellungsverfahren und eigenschaften von styrol-butadien random-copolymer/poly(arylenether) zusammensetzungen

Legal Events

Date Code Title Description
8363 Opposition against the patent